Biotech, developing and developed countries vaccine manufacturers COVID-19 press briefing
This press briefing took stock of the progress achieved in developing and scaling up COVID-19 vaccines production, and addressed the challenges that need to be tackled.
Read more
Biotech, developing and developed countries vaccine manufacturers COVID-19 press briefing
The press briefing will take stock of the contribution and difficulties of scaling up COVID-19 vaccines production, and the short and longer term challenges that need to be addressed.
Read more
Biotechs, developing countries vaccine manufacturers and pharma unite behind a proposal to G20 and G7 offering a practical solution for better access to vaccines for future pandemics
The vaccines innovators and manufacturers who have produced over 15 billion COVID-19 vaccines to date are making a proposal that would ensure new vaccines developed for future global pandemics would reach all priority populations equally, wherever they live, thereby addressing a key element of vaccine inequity that hampered the roll out of COVID-19 vaccines in...
Read moreSlides Airfinity – 5th GLOBAL BIOPHARMA CEO / TOP EXECS VIRTUAL PRESS BRIEFING – COVID-19 (8 December 2020)
Read moreAs COVID-19 vaccine output estimated to reach over 12 billion by year end and 24 billion by mid-2022, innovative vaccine manufacturers renew commitment to support G20 efforts to address remaining barriers to equitable access
This month, COVID-19 vaccine manufacturing output will pass the 9.3 billion dose mark. The biopharmaceutical industry renews its May commitment to the G20 to collaborate with governments to support effective solutions to urgently address vaccine equity. At current production rates, swiftly rolling out vaccines to those who still need them looks achievable, if the political...
Read moreCOVID-19 vaccine makers invite G20 leaders to support the five steps to urgently advance COVID-19 vaccine equity
21 May 2021 – Innovative vaccine manufacturers and biotech companies are at the forefront of the global effort to develop and manufacture COVID-19 vaccines. Despite a massive effort to scale up and produce billions of vaccine doses, COVID-19 vaccines currently are not equally reaching all priority populations worldwide. The innovative vaccine manufacturers and biotech companies...
Read moreInterview – Al Jazeera – How COVID-19 vaccine manufacturers are collaborating with governments to ensure that an effective and safe vaccine is available everywhere in the world
Watch full interview hereThomas Cueni, IFPMA Director General, spoke to Al Jazeera English, on the side lines of the World Health Summit, about collaboration between the pharmaceutical industry and governments to make sure COVID 19 vaccines are available in poorer countries; as well as industry’s commitment to the most rigorous regulatory scrutiny. Maryam Nemazee Also...
Read more11 billion COVID-19 vaccines produced in 2021 has resulted in the biggest immunization campaign in human history and 2022 will require more and better vaccine redistribution and innovation
The Biotechnology Innovation Organization (BIO), Developing Countries Vaccine Manufacturers’ Network (DCVMN), and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing many of the companies behind the historic scale up of manufacturing of vaccines, released independent data that confirms production of COVID-19 vaccines scaled up from zero to 11,2 billion doses in just one year.
Read moreInterview – BBC World News – COVID-19 vaccine manufacturers want to reassure the public and send a message to regulators
Interview – BBC World News – COVID-19 vaccine manufacturers want to reassure the public and send a message to regulators 10 September 2020 – By Thomas B. Cueni Thomas Cueni, IFPMA Director General, spoke to BBC World New programme Outside Source, on 8 September 2020, about the need for rigorous regulatory standards for approval of...
Read moreIFPMA supports call for extension of TRIPS compliance deadline for least developed countries
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) today expressed the research-based pharmaceutical industry’s support for calls to extend the deadline for Least-Developed Countries to comply with the provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Mr. David Brennan, President of the IFPMA and CEO of AstraZeneca, said: “We recognize...
Read more